Kornimate/medical-research-clean huggingface dataset:
association of triglyceride-glucose index with cardiac hemodynamics

Conditions: Obesity

Summary: 1) to estimate the prevelance of ir in obese patients based on tyg index . 2) to screen early cardiovascular abnormalities in obese asymptomatic patients using conventional echocardiography and electrocardiogram . 3) to detect association of cardiovascular hemodynamics with tyg index . assess cardiovascular risk in obese patients .

obesity has been a health problem of growing significance all over the world; its prevalence is increasing in both developed and developing countries . according to who data, 39% of the global population above 18 years of age are overweight and of these, 13% are obese. obesity is a chronic (long-term) medical disease. both overweight (bmi \>25 kg/m2) and obesity defined as a ( body mass index, or bmi, of \>30 kg/m2) are associated with an increased risk of cardiovascular diseases. this is a consequence on the one hand of obesity itself and on the other hand of associated medical conditions (hypertension, diabetes, insulin resistance ,stroke ,sleep apnea, osteoarthritis, gallstones, high cholesterol, gout, and certain types of cancer ) . obesity produces a variety of hemodynamic alterations that may cause changes in cardiac morphology which predispose to left and right ventricular dysfunction. various neurohormonal and metabolic alterations commonly associated with obesity may contribute to these abnormalities of cardiac structure and function. cardiovascular diseases, including heart failure (hf), atrial fibrillation (af), and coronary artery disease (cad), are often associated with obesity. the duration of obesity has a direct impact on the incidence of cardiovascular disease.the triglyceride-glucose (tyg) index is the logarithmized product of fasting triglycerides and fasting glucose and has been proposed as the alternative indicator of ir ( with sensitivity 96.5 % and specificity 85% ) due to its relevance to lipotoxicity and glucotoxicity compared to homeostatic model assessment for insulin resistance (homa-ir), which is expensive due to insulin measurement .tyg index has demonstrated a close relationship with cardiometabolic outcomes, namely diabetes, arterial stiffness, hypertension, cardiovascular disease (cvd), stroke and obesity-related cancers in previous studies.

Eligibility criteria:
inclusion criteria: * the study will include obese patients over two years duration ( jan 2023 to jan 2024 )( age above 18 years old ; written consent will be obtained ) exclusion criteria: * history of heart failure or patient known to have congenital heart disease, primary or secondary myocardial disease . medications associated with weight gain . patients with previous cardiac diseases (arrhythmias - valve disease). patients who have recently used glucocorticoids or antipsychotics. patients on statins .

Keywords: tyg index cardiac hemodynamics
using vedolizumab-800cw to gain insight into local drug distribution and mucosal target cells in ibd patients

Conditions: Crohn Disease; Colitis, Ulcerative

Summary: summary vision study crohn's disease (cd) and ulcerative colitis (uc) are chronic idiopathic inflammatory bowel diseases (ibd). vedolizumab is a humanized monoclonal antibody against α4β7 integrin, capable of blocking the migration of several immune cells across endothelium expressing madcam-1. vedolizumab is expensive and primary non-response is high in both cd and uc. currently there are no predictors of response to vedolizumab and the actual mechanism of action has not yet been elucidated. to clarify the mechanism of action and gain better understanding of the high primary non-response rates, the university medical center groningen (umcg) developed a tracer fluorescently labeling vedolizumab. this study aims to gain insight into vedolizumab distribution and concentrations in the gut. the current study aims to identify the vedolizumab target cells in the inflamed gut mucosa using quantitative fluorescence molecular imaging (fmi). by gaining insight into local vedolizumab concentrations, drug distribution and by discovering target cells, we expect to gain insight into the mechanism of action of vedolizumab.


Eligibility criteria:
inclusion criteria: * established diagnosis of ibd, or ulcerative colitis (uc) or crohn's disease (cd). * vedolizumab naïve and eligible for vedolizumab treatment. * age: 18 years or older. * written informed consent. exclusion criteria: * prior vedolizumab treatment * vedolizumab contraindicated as therapy * pregnancy or breast feeding. * patients younger than 18 years old

Keywords: fluorescence endoscopy vedolizumab-800cw
improving personal recovery after depression with a blended module (stairs)

Conditions: Depression

Summary: almost all mental healthcare treatments of depression focus on symptomatic recovery. however, such recovery does not inherently mean that personal recovery is reached. in fact, many persons still experience functional impairments after symptomatic recovery. as this has a negative influence on daily life, a new blended module (stairs) was developed to promote personal recovery in persons that are in the final stage of symptomatic recovery from depression. the current study will investigate the efficacy of stairs, by adding stairs to care as usual and comparing it with care as usual. it is hypothesized that stairs will have a positive effect on personal recovery and that this effect is larger than in the control group.

the study uses a mixed methods design to determine efficacy and underlying mechanisms contributing to the effect of the stairs-training. one hundred forty adults, who are in the last phase of their depression treatment, will be enrolled and randomized (1:1) to (1) a group receiving the stairs-training next to care as usual (cau) or (2) a group receiving cau added with three information letters. level of personal recovery, symptom severity, empowerment and control will be determined at baseline, at the end of the program (8 weeks) and at 6 months follow up. approximately fifteen participants from the stairs group will be asked about their experiences with the different elements of the program and the perceived effects, in a semi-structured interview at the end of the program.

Eligibility criteria:
inclusion criteria: * age 18 to 65 years old * being in the last phase (recovery phase) of treatment for a diagnosed major depressive disorder; psychological treatment is expected to end within three months or treatment is finished within the past 3 months and patient receives an aftercare and/or maintenance antidepressant treatment. * no more than moderate depression severity: score of \<38 on the inventory of depressive symptomatology - self rated (ids-sr). * the willingness to participate: an affirmative response to the question 'after being explained what participation means for you, are you willing to participate?'. exclusion criteria: * bipolar depression or depression with psychotic features. * comorbid schizophrenia spectrum or other psychotic disorder. * comorbid moderate or severe dependence of alcohol or drugs. * neurological disorder (e.g., dementia). * insufficient command of the dutch language. * cognitive problems or indication of low iq (i.e.\< 80). * not in possession of a pc or smartphone. * having been referred to a different mental health service for other mental problems

Keywords: personal recovery
multimodal haptic feedback for plantar sensory substitution

Conditions: Hypoesthesia

Summary: the study will explore the use of a haptic device for sensory substitution in individuals with a movement disorder that has caused loss of plantar sensation. the haptic device consists of two components. the first element is a flexible insole with embedded pressure-sensing elements that transmit the spatial patterns of applied foot pressure over time. the second element is a haptic receiver with embedded actuators that vibrate or heat up in proportion to the transmitted pressure patterns, thus substituting the patient's lost plantar sensation.

objectives: 1. identify a systematic, methodical approach to determine whether different users of our haptic device can perceive and use vibrational and thermal feedback in order to correct their posture in real-time. 2. evaluate whether a haptic device can be used to guide users to maintain a prescribed pattern of pressure on their feet during standing and walking. 3. investigate whether a haptic device can improve outcomes on motor evaluation tasks.

Eligibility criteria:
inclusion criteria: * able to ambulate 10 meters with or without assistance * able and willing to give written consent and comply with study procedures exclusion criteria: * unable to give written consent or comply with study procedures * unable to perceive unsafe levels of heat in relevant areas * has a motor complete spinal cord injury * have transfemoral (above knee) amputation * any condition that would prevent the safe completion of study activities, as determined by the principal investigator

Keywords: plantar sensation
fosamax bone loss study: alendronate to prevent bone loss

Conditions: Perimenopausal Bone Loss

Summary: this is a study to determine if fosamax (alendronate), a medication approved by the food and drug administration (fda) for the prevention and treatment of osteoporosis in postmenopausal women, is effective in decreasing the rate of bone loss which often begins to increase in the three to five years preceding the menopause (perimenopausal transition). during the three to five years prior to the menopause, the rate of bone loss increases. one way that physicians treat this is with oral contraceptive medication. however, the incidence of complications from oral contraceptives after the age of 40 increases. therefore, a non-hormonal means of preventing bone loss should be useful. fosamax (alendronate) is in a class of compounds called bisphosphonates. this study is being done to determine whether fosamax can be used to prevent the increased rate of bone loss during the perimenopausal transition.


Eligibility criteria:
inclusion criteria: * women ages 40-54 with symptomology of perimenopause including hot flashes, irregular periods and vaginal dryness. exclusion criteria: * women should not be on hormone replacements, oral contraceptives, or bone mineral enhancing medications (bisphosphonates, selective estrogen receptor modulators \[serm's\], parathyroid hormone \[pth\], calcitriol, fluorides) * they should not have any abnormalities of the esophagus which delay esophageal emptying * they should not have hypocalcemia or severe kidney disease * their bone mineral density (t-score) should not be greater than 2 standard deviations.

Keywords: perimenopausal bone loss
comparison of nutrition education alone or with acupuncture for weight loss in breast cancer patients post-chemotherapy

Conditions: Breast Cancer

Summary: this study looks at the benefit of adding acupuncture to nutrition education for weight loss in women with early stage breast cancer post-chemotherapy.

obesity and weight gain are significant concerns for breast cancer survivors. given the adverse consequences of weight gain after diagnosis, continued efforts to identify appropriate weight management interventions aimed at promoting overall health and long term survivorship are needed. in this study, the investigators will examine whether adding acupuncture to a nutrition education program for weight loss could improve short and long term weight loss among breast cancer survivors post treatment with chemotherapy.

Eligibility criteria:
inclusion criteria: * woman with a diagnosis of breast cancer, stage i, ii, or iii * age ≥ 18 * ecog performance status ≤ 1 * received treatment for breast cancer, and treatment must have been completed at least 2 weeks prior to enrollment in trial, but no longer than 1 year post-treatment. * bmi ≥ 30 * adequate bone marrow and organ function as determined by the consenting/enrolling investigator * signed informed consent * any receptor status * participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled visits, and examinations exclusion criteria: * current chemotherapy or radiation therapy. participants in study may still be receiving hormone or herceptin treatment. * diagnosis of metastatic breast cancer * participation in other diet-based weight loss programs (ie. patient should not be currently enrolled in weight watchers, jenny craig, nutrisystem, etc.) * current use of commercial or natural/herbal weight loss supplements * major surgery within 1 month of starting study program and patients must have recovered from any effects of major surgery * other malignancies within the past three years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin * personal history of an eating disorder * other serious, uncontrolled medical disorder, non-malignant systemic disease, or active, uncontrolled infection (including uncontrolled hiv, hepatitis b or c), or any psychiatric disorder that prohibits obtaining informed consent
a study of (interleukin-12) il-12 in patients with acute myelogenous leukemia (aml)

Conditions: Acute Myeloid Leukemia

Summary: this is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (aml) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant. this study will see whether modifying a patient's aml cells to produce il-12 and giving it back to the patient is safe and useful in patients with aml that cannot have bone marrow transplants.


Eligibility criteria:
inclusion criteria: * patient with aml and \>=18 years of age. * agrees to participate in the study and signs the informed consent * viable cells are available for successful modification * first or higher complete remission and have high risk features of relapse. * patients who have received prior treatment and are not in remission must have stable white blood cell count and are not receiving any chemotherapy or desiring further intensive treatment. * less than 10% blast cells in the bone marrow following induction or re-induction therapy and not desiring further intensive treatment. * acceptable creatinine, aspartate transaminase (ast), alkaline phosphatase (alp), bilirubin lab results. * agree to use contraception * not pregnant * able to comply with study procedures exclusion criteria: * eastern cooperative oncology group (ecog) performance status \>2 * known persistent infection * known central nervous system (cns) disease * greater than 10% blasts in the bone marrow or circulating blast cells * life expectancy \< 2 months * receiving any chemotherapy, corticosteroids, cox2 inhibitors or any non-drug therapies with the intent of altering the immune response or kill leukemic cells within one week prior to infusion of il-12, except azacytidine. * patients who are hiv positive.

Keywords: recurrent
registry for advanced endoscopy

Conditions: Cholangiocarcinoma; Pancreatic Cancer; Sclerosing Cholangitis

Summary: observational registry including endoscopic diagnostic and therapeutic interventions in the gastrointestinal tract


Eligibility criteria:
inclusion criteria: * clinical indication for endoscopic intervention/procedure exclusion criteria: * no informed consent * age \<18 years
immune checkpoint inhibitors and atherosclerotic plaque volume

Conditions: Non-small Cell Lung Cancer

Summary: in this study, investigators plan to test whether immune checkpoint inhibitor (ici) treatment leads to an accelerated progression of atherosclerosis in patients with lung cancer. atherosclerosis is an immune-mediated inflammatory disease and these same checkpoints being targeted for cancer are critical negative regulators of atherosclerosis in animal and cellular models. aortic plaque progression will be compared between cases (on ici) and controls from pre-ici to post-ici among patients with non-small cell lung cancer. groups will be matched for age, cancer type and stage and cardiovascular risk factors. traditional markers of cardiovascular (cvd) risk and cancer-specific factors (ici mono- and combination therapy, number of cycles, occurrence of immune-related adverse events, chest radiation, steroid use) will be associated with the change in aortic plaque volume.


Eligibility criteria:
inclusion criteria: cases: * subjects with non-small cell lung cancer treated with immune checkpoint inhibitors. * available contrast enhanced ct scans of the chest both immediately pre-ici (\< 1 month) and latest follow-up. controls: * subjects with non-small cell lung cancer, age, cancer stage and cardiovascular risk factor matched to cases. * available contrast enhanced ct scan of the chest at two time-points at a similar interval between scans as the cases. exclusion criteria: none

Keywords: non-small cell lung cancer immune checkpoint inhibitor atherosclerosis
comparative analysis of apache ii and p-possum

Conditions: External Causes of Morbidity and Mortality

Summary: to compare apache ii and p-possum scoring system in emergency laparotomy.

to compare apache ii and p-possum scoring system in predicting postoperative mortality in patients undergoing emergency laparotomy.

Eligibility criteria:
inclusion criteria: * all patients above 18 years of age undergoing emergency laparotomy at tata main hospital form 01st december 2013 to 30th november 2014 will be included in the study. exclusion criteria: * patients willingly seeking referral to a different hospital
soy isoflavone in combination with radiation therapy and cisplatin in scc of the head and neck

Conditions: Cancer of Head and Neck

Summary: the purpose of this study is to determine if soy supplementation during chemotherapy and radiation therapy will decrease side effects caused by treatment. long-lasting dry mouth is a side effect of the standard treatment, and we are testing whether soy supplementation during treatment may reduce this symptom and other side effects of chemoradiation.

concurrent chemoradiation is the standard of care for locally advanced squamous cell carcinoma of the head and neck (scchn). improving the outcome for patients with this disease remains a major challenge.

Eligibility criteria:
inclusion criteria: * biopsy proven squamous cell carcinoma of the head and neck (scchn) * primary disease site involving the oropharynx * clinical stage iii or iv * age ≥ 18 * karnofsky performance status (kps) ≥ 70 * adequate bone marrow, kidney, and hepatic function (no laboratory value \> 2 times the normal limit) * amylase (0-160 u/l) and lipase (0-130 u/l) levels within 1.5 times the range of normal exclusion criteria: * prior history of scchn * prior history of radiation to the head and neck region * kps \< 70 * soy allergy * contraindication to cisplatin chemotherapy or plans to alter or reduce cisplatin therapy * any head and neck cancer of non-squamous histology * any head and neck subsite other than oropharynx (including unknown primary site) * patients who are pregnant or lactating * patients who may benefit from surgical resection

Keywords: soy isoflavone radiation therapy cisplatin
impact of sterilization technique on incidence of urinary tract infection after cystoscopy

Conditions: Urinary Tract Infections

Summary: the purpose of this study is to verify that the incidence rate of urinary tract infections after a routine outpatient cystoscopy is the same for non-sterile (clean) and sterile procedural techniques.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * patients undergoing routine outpatient flexible cystoscopy exclusion criteria: * patients who have had a urinary tract infection within 3 months prior to flexible cystoscopy * patients with an indwelling catheter

Keywords: cystoscopy
mcc-24-gyn-11: comparison of nodal sampling in endometrial cancer

Conditions: Endometrial Cancer

Summary: this study aims to estimate the recurrence-free survival rates in women with endometrial cancer treated with selective versus sentinel node surgical staging. this study will gather information to help determine the best way to evaluate lymph nodes during surgery for endometrial cancer.


Eligibility criteria:
inclusion criteria: * surgical candidate for complete hysterectomy and bilateral salpingooophorectomy with pelvic and aortic lymphadenectomy * histologically or cytologically confirmed carcinoma of the endometrium confined to the uterine corpus * no clinical evidence of extra-uterine disease on pre-operative evaluation. preoperative evaluation to rule-out extra-uterine disease may include a ct scan, mri or ultrasound. note: preoperative imaging is not mandatory for study enrollment. * prior systemic chemotherapy is allowed so long as it was at least five years prior to study enrollment, and there is no evidence of disease after such therapy. neoadjuvant chemotherapy for this endometrial cancer is not allowed. * life expectancy (estimated survival) of at least 6 months. * ast(sgot)/alt(sgpt) \< 3.0x upper limit of normal * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * gog performance status greater than 2 (appendix ii) * uterine sarcoma * clinical evidence of disease that extends beyond the uterus, including the presence of suspicious aortic or inguinal nodes on imaging or clinical exam * previous vaginal, pelvic or abdominal irradiation * chemotherapy, hormone therapy or immunotherapy directed at the present disease * previous pelvic lymphadenectomy or retroperitoneal surgery * patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen should be excluded * known allergy to iodine or indocyanine green (icg) tracer, or allergic reactions to compounds of similar chemical or biologic composition * patients with uncontrolled intercurrent illness * patients with psychiatric illness/social situations that would limit compliance with study requirements * pregnant or lactating women. women of child-bearing potential will be excluded if they have a positive serum/urine pregnancy test

Keywords: selective surgical staging lymphadenectomy